Table 3.

Cox regression and Fine-Gray competing risk regression analysis of non-neoplastic and neoplastic mortality risk over 22 years of follow-up after ACS with the interaction for risks between the six geographic areas after excluding patients who had malignancy and were still alive (n = 519).

Variable	Unadjusted			Fully adjusted*
	HR (95% CI)	Z	p	HR (95% CI)	Z	p
Cox regression
Non-neoplastic mortality (n = 321)
urban-rural areas	0.9 (0.7–1.0)	-0.9	0.33	0.9 (0.7–1.1)	-0.8	0.43
southern-northern provinces	1.2 (1.0–1.3)	2.3	0.02	1.0 (0.9–1.2)	0.1	0.95
Interaction (urban/rural areas and south to north provinces)	1.0 (0.8–1.3)	0.2	0.82	1.2 (0.9–1.5)	1.1	0.28
Neoplastic mortality (n = 99)
urban-rural areas	1.2 (0.8–1.8)	1.0	0.30	1.3 (0.9–2.0)	1.4	0.15
southern-northern provinces	1.2 (0.9–1.5)	1.5	0.13	1.1 (0.9–1.4)	0.7	0.46
Interaction (urban/rural areas and south to north provinces)	2.0 (1.2–3.3)	2.8	0.005	2.2 (1.4–3.6)	3.2	0.002
Fine-Gray competing risk regression analysis
	SHR (95% CI)	Z	p	SHR (95% CI)	Z	p
Non-neoplastic mortality (n = 321)
urban-rural areas	0.9 (0.7–1.1)	-1.2	0.23	0.9 (0.7–1.1)	-1.1	0.28
southern-northern provinces	1.1 (1.0–1.3)	1.6	0.10	1.0 (0.9–1.2)	0.03	0.97
Interaction (urban/rural areas and southern to northern provinces)	0.9 (0.7–1.2)	-0.5	0.60	0.9 (0.7–1.2)	-0.4	0.70
Neoplastic mortality (n = 99)
urban-rural areas	1.3 (0.9–1.9)	1.2	0.21	1.3 (0.9–1.9)	1.4	0.17
southern-northern provinces	1.1 (0.9–1.4)	0.7	0.49	1.1 (0.9–1.4)	1.0	0.31
Interaction (urban/rural areas and southern to northern provinces)	1.9 (1.2–3.1)	2.5	0.01	2.0 (1.2–3.4)	2.7	0.007

CI, confidence interval; HR, hazard ratio; SHR, sub-hazard ratio.

P-values were calculated for log-transformed data. *Adjusted for age, sex, smoking, education level, alcohol consumption, baseline serum cholesterol, presence of heart failure at admission, and anti-platelet and beta-blockers time intensity treatment per cent during follow-up.